CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial in breast cancer, expanding on the broad development program for its lead product candidate, the novel, oral triple VEGF receptor inhibitor AV-951. This is the third cancer indication being explored by AVEO for the potential combined use of AV-951 with leading targeted agents and/or chemotherapeutic regimens. The Company launched the Phase 1b portion of this new open-label study at leading cancer institutions in the U.S. and E.U., to evaluate the combined daily dose of escalating, sequential doses of oral AV-951 with standard weekly intravenous administration of paclitaxel (Taxol™) in patients with advanced breast cancer.
